{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:35:41Z","timestamp":1777602941152,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bmc.2024.117892","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T21:13:36Z","timestamp":1724447616000},"page":"117892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugs"],"prefix":"10.1016","volume":"112","author":[{"given":"Jean-Philippe","family":"Surivet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed","family":"Aissaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bezen\u00e7on","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Kiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs","family":"L\u00fcthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Marck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Masse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens-Uwe","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Sweatman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117892_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000514961","article-title":"Twenty-three years of hypocretins: the \u201cRosetta Stone\u201d of sleep\/arousal circuits","volume":"45","author":"de Lecea","year":"2021","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.bmc.2024.117892_b0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cmdc.201200025","article-title":"Discovery of [(2R,5R)-5-[(5-fluoropyridin-2-yl)oxy]methyl-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties","volume":"7","author":"Coleman","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117892_b0015","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1021\/acs.jmedchem.5b00217","article-title":"Discovery of (1R,2S)-2-30z-2-(3-fluorophenyl)-N-(5-fluor opyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist","volume":"58","author":"Yoshida","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117892_b0020","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/cmdc.202000453","article-title":"The quest for the best dual orexin receptor antagonist (daridorexant) for the treatment of insomnia disorders","volume":"15","author":"Boss","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117892_b0025","unstructured":"Hcccighlights of prescribing information of Belsomra, Dayvigo and Quviviq can be downloaded from the followings URLs respectively: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204569s006lbl.pdf; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212028s000lbl.pdf; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214985s000lbl.pdf."},{"key":"10.1016\/j.bmc.2024.117892_b0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-term safety and tolerability of daridorexant in patients with insomnia disorder","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmc.2024.117892_b0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmc.2024.117892_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115489","article-title":"Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"28","author":"Futamura","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117892_b0045","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","article-title":"Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study","volume":"239","author":"Uchiyama","year":"2022","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.bmc.2024.117892_b0050","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th Edition ed.; 2013. doi: 10.1176\/appi.books.9780890425596.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1016\/j.bmc.2024.117892_b0055","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-third edition: highlights and modifications","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.bmc.2024.117892_b0060","first-page":"33","article-title":"sleep disorders: circadian rhythm sleep-wake disorders","volume":"460","author":"Burman","year":"2017","journal-title":"FP Essentials"},{"key":"10.1016\/j.bmc.2024.117892_b0065","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00420-018-1386-4","article-title":"Sleep and alertness in shift work disorder: findings of a field study","volume":"92","author":"Vanttola","year":"2019","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1016\/j.bmc.2024.117892_b0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jsmc.2022.03.003","article-title":"Epidemiology of insomnia: prevalence, course, risk factors, and public health burden","volume":"17","author":"Morin","year":"2022","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.bmc.2024.117892_b0075","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/acer.13217","article-title":"Alcohol dependence and its relationship with insomnia and other sleep disorders","volume":"40","author":"Chakravorty","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.bmc.2024.117892_b0080","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1532-5415.2010.03288.x","article-title":"Greater risk of Alzheimer's disease in older adults with insomnia","volume":"59","author":"Osorio","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.bmc.2024.117892_b0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40263-023-01020-9","article-title":"Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem","volume":"37","author":"Di Marco","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmc.2024.117892_b0090","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.117.241596","article-title":"The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468","volume":"362","author":"Treiber","year":"2017","journal-title":"J Pharmacol Exp Therap"},{"key":"10.1016\/j.bmc.2024.117892_b0095","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.xphs.2019.02.005","article-title":"Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration","volume":"108","author":"Feng","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2024.117892_b0100","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1021\/tx0496791","article-title":"Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites","volume":"18","author":"Gan","year":"2005","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2024.117892_b0105","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/acs.jmedchem.7b00969","article-title":"Relevance of half-life in drug design","volume":"61","author":"Smith","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117892_b0110","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1021\/acs.jmedchem.8b01263","article-title":"Clearance in drug design","volume":"62","author":"Smith","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117892_b0115","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1039\/C5MD00074B","article-title":"Discovery and optimisation of 1-acyl-2-benzylpyrrolidines as potent dual orexin receptor antagonists","volume":"6","author":"Williams","year":"2015","journal-title":"MedChemComm"},{"key":"10.1016\/j.bmc.2024.117892_b0120","unstructured":"Coleman PJ, Mercer SP, Roecker AJ. PCT WO2008\/150364 A1; 2008."},{"key":"10.1016\/j.bmc.2024.117892_b0125","unstructured":"Bolli M, Boss C, Brotschi C, Heidmann B, Sifferlen T, Williams JT. PCT WO2013\/068935A1; 2013."},{"key":"10.1016\/j.bmc.2024.117892_b0130","unstructured":"For the first disclosure of 2-triazolyl benzamides in orexin receptor antagonists: Coleman PJ, Schreier J. PCT WO2006\/110626 A1; 2006."},{"key":"10.1016\/j.bmc.2024.117892_b0135","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1021\/tx300091x","article-title":"In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs","volume":"25","author":"Thompson","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2024.117892_b0140","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1016\/S0040-4039(01)98422-9","article-title":"Intramolekulare cycloadditionen von azomethiniminen, teil I: reaktion von ungesaettigten aldehyden mit n-acyl-n\u2032-alkylhydraziden","volume":"11","author":"Oppolzer","year":"1970","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2024.117892_b0145","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1021\/jo960057x","article-title":"Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures","volume":"61","author":"Abdel-Magid","year":"1996","journal-title":"J Org Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T22:45:49Z","timestamp":1726353949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624003067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":29,"alternative-id":["S0968089624003067"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117892","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugs","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117892"}}